[Residual risk in cardiovascular prevention]

Area of Science:

• Cardiology
• Preventive Medicine
• Clinical Trials

Background:

• Significant advancements in identifying cardiovascular disease (CVD) risk factors have been made.
• Highly effective CVD prevention tools, such as statins, have been developed and widely implemented.
• Despite these advances, a substantial residual risk of cardiovascular events persists, particularly noted in major clinical trials.

Purpose of the Study:

• To highlight the ongoing challenge of residual cardiovascular risk.
• To emphasize the need for novel and efficient preventive strategies in cardiovascular medicine.
• To guide future research directions in CVD prevention.

Main Methods:

• Analysis of major outcome trials focusing on statin therapy.
• Evaluation of the reported residual risk of cardiovascular events in trial participants.
• Synthesis of current knowledge on CVD risk factors and prevention tools.

Main Results:

• Residual risk of cardiovascular events remains high, estimated at 60-70% in major statin trials.
• Current prevention strategies, while effective, do not fully eliminate cardiovascular event risk.
• The persistence of residual risk underscores limitations of existing therapeutic approaches.

Conclusions:

• The high residual risk of cardiovascular events necessitates a re-evaluation of current preventive strategies.
• Awareness of this persistent problem is crucial for directing research towards more effective and efficient solutions.
• Future efforts must focus on developing innovative approaches to further mitigate cardiovascular risk.